Denali Therapeutics (STU:4DN) Cyclically Adjusted FCF per Share: €-1.46 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4DN Denali Therapeutics Inc STU:4DN
39 GF Score
Price €21.91
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Denali Therapeutics Cyclically Adjusted FCF per Share?

Denali Therapeutics STU:4DN +4.78% 39 Cyclically Adjusted FCF per Share is €-1.46 as of Jun. 2026. GuruFocus rates STU:4DN with a GF Score™ of 39/100 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Denali Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.587. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.46 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-20), Denali Therapeutics's current stock price is €21.91. Denali Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-1.46. Denali Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Denali Therapeutics  (STU:4DN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Denali Therapeutics Cyclically Adjusted FCF per Share Related Terms


Denali Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Denali Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics Cyclically Adjusted FCF per Share Chart

Denali Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Denali Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.46

STU:4DN vs RCUS, ALMS, ELVN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Denali Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Denali Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Denali Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:4DN
39GF Score
Denali Therapeutics Inc STU:4DN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Denali Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Denali Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.587/333.9520*333.9520
=-0.587

Current CPI (Jun. 2026) = 333.9520.

Denali Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 0.000 236.525 0.000
201612 -0.281 241.432 -0.389
201703 -2.040 243.801 -2.794
201706 -0.237 244.955 -0.323
201709 -0.227 246.819 -0.307
201712 -0.187 246.524 -0.253
201803 0.299 249.554 0.400
201806 -0.391 251.989 -0.518
201809 -0.326 252.439 -0.431
201812 0.855 251.233 1.137
201903 -0.301 254.202 -0.395
201906 -0.495 256.143 -0.645
201909 -0.315 256.759 -0.410
201912 -0.472 256.974 -0.613
202003 -0.489 258.115 -0.633
202006 -0.367 257.797 -0.475
202009 -0.005 260.280 -0.006
202012 3.118 260.474 3.998
202103 -0.369 264.877 -0.465
202106 -0.371 271.696 -0.456
202109 -0.302 274.310 -0.368
202112 -0.497 278.802 -0.595
202203 -0.564 287.504 -0.655
202206 -0.352 296.311 -0.397
202209 -0.516 296.808 -0.581
202212 -0.550 296.797 -0.619
202303 -0.421 301.836 -0.466
202306 -0.779 305.109 -0.853
202309 -0.609 307.789 -0.661
202312 -0.669 306.746 -0.728
202403 -0.713 312.332 -0.762
202406 -0.528 314.175 -0.561
202409 -0.335 315.301 -0.355
202412 -0.499 315.605 -0.528
202503 -0.738 319.799 -0.771
202506 -0.402 322.561 -0.416
202509 -0.523 324.800 -0.538
202512 -0.487 324.054 -0.502
202603 -0.620 330.213 -0.627
202606 -0.587 333.952 -0.587

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1.46 mean?
Denali Therapeutics (STU:4DN) has a Cyclically Adjusted FCF per Share of €-1.46 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Denali Therapeutics and its competitors.
Is Denali Therapeutics' Cyclically Adjusted FCF per Share too high?
Denali Therapeutics' current Cyclically Adjusted FCF per Share is €-1.46. Overall, Denali Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Cyclically Adjusted FCF per Share compare to RCUS and ALMS?
Denali Therapeutics' Cyclically Adjusted FCF per Share of €-1.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Denali Therapeutics and its competitors. Denali Therapeutics's current Cyclically Adjusted FCF per Share is €-1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Denali Therapeutics (STU:4DN) is currently considered Significantly Overvalued. The current Cyclically Adjusted FCF per Share is €-1.46. Denali Therapeutics' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Denali Therapeutics (STU:4DN), the current Cyclically Adjusted FCF per Share is €-1.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Denali Therapeutics Business Description

Other Exchanges DNLI:USAD2NL34:Brazil
Address 161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
39GF Score

Get the complete analysis for STU:4DN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.91
Price